Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recatistimab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Recatistimab (SHR-1916) is a humanized monoclonal antibody targeting the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an inhibitory immune checkpoint receptor expressed on T cells and natural killer (NK) cells. TIGIT suppresses immune responses by binding to ligands such as CD155 (PVR) on antigen-presenting cells or tumor cells. Recatistimab acts as an antagonist, blocking the interaction between TIGIT and its ligands to relieve immunosuppression and enhance the anti-tumor activity of the immune system. Developed by Jiangsu Hengrui Pharmaceuticals, recatistimab is being evaluated in clinical trials for various solid tumors, frequently in combination with other immunotherapies like the PD-L1 inhibitor adebrelimab, to improve clinical outcomes in patients with advanced malignancies such as head and neck squamous cell carcinoma (HNSCC).
- Other names
- Recatistimab
02
Targets
IL-2Rα (Interleukin-2 receptor subunit alpha)IL2RG (Interleukin-2 receptor gamma subunit)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on recatistimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recatistimab.